Australia markets open in 9 hours 3 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
20.91-0.50 (-2.34%)
At close: 04:00PM EST
20.91 0.00 (0.00%)
After hours: 06:03PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 2.44B
Enterprise value 2.08B
Trailing P/E 25.80
Forward P/E 21.01
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.71
Price/book (mrq)4.58
Enterprise value/revenue 5.90
Enterprise value/EBITDA 17.19

Trading information

Stock price history

Beta (5Y monthly) 0.68
52-week change 3-11.85%
S&P500 52-week change 322.93%
52-week high 331.18
52-week low 317.57
50-day moving average 320.57
200-day moving average 321.84

Share statistics

Avg vol (3-month) 3695.21k
Avg vol (10-day) 31.22M
Shares outstanding 5115.93M
Implied shares outstanding 6N/A
Float 896.33M
% held by insiders 19.97%
% held by institutions 171.30%
Shares short (14 Nov 2021) 48.96M
Short ratio (14 Nov 2021) 412.62
Short % of float (14 Nov 2021) 411.71%
Short % of shares outstanding (14 Nov 2021) 47.76%
Shares short (prior month 14 Oct 2021) 48.4M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 30.17%
Operating margin (ttm)33.53%

Management effectiveness

Return on assets (ttm)13.21%
Return on equity (ttm)20.67%

Income statement

Revenue (ttm)352.89M
Revenue per share (ttm)3.03
Quarterly revenue growth (yoy)11.40%
Gross profit (ttm)348.29M
EBITDA 119.18M
Net income avi to common (ttm)106.45M
Diluted EPS (ttm)0.83
Quarterly earnings growth (yoy)40.90%

Balance sheet

Total cash (mrq)361.33M
Total cash per share (mrq)3.13
Total debt (mrq)1.05M
Total debt/equity (mrq)0.19
Current ratio (mrq)8.98
Book value per share (mrq)4.68

Cash flow statement

Operating cash flow (ttm)153.54M
Levered free cash flow (ttm)113.33M